Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly with chemotherapy is approved by the FDA for endometrial cancer
August 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline), followed by dostarlimab-gxly as a single agent, was approved by the Food and Drug Administration for the treatment of primary advanced or recurrent endometrial cancer (EC..
dMMR, Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer
Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed during or after a prior ..
dMMR advanced solid tumors, Dostarlimab-gxly, GARNET Trial, GlaxoSmithKline LLC, Jemperli, NCT02715284, VENTANA MMR RxDx
Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given accelerated approval by the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumours, as dete..
Jemperli, platinum-containing regimen, RECIST
Dostarlimab-gxly receives accelerated approval from the FDA for dMMR endometrial cancer
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) received accelerated approval from the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, a..